Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees

References

• Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature 2013; 496(7446):504-7. Epub 2013/04/09; PMID:23563266; http://dx.doi.org/10.1038/nature12060
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380(9853):1559-67. Epub 2012/09/15; PMID:22975340; http://dx.doi.org/10.1016/S0140-6736(12)61428-7
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384(9951):1358-65; PMID:25018116; http://dx.doi.org/10.1016/S0140-6736(14)61060-6
   PubMed Web of Science ®Google Scholar
• Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Eng J Med 2015; 372(2):113-23; http://dx.doi.org/10.1056/NEJMoa1411037
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Eng J Med 2015; 373(13):1195-206; http://dx.doi.org/10.1056/NEJMoa1506223
   PubMed Web of Science ®Google Scholar
• Capeding MR, Laot T, Boaz M, Wartel-Tram A, Crevat D. Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period. Trials Vaccinol 2015; 4:19-23; http://dx.doi.org/10.1016/j.trivac.2015.03.002
   Google Scholar
• Thomas SJ, Endy TP. Current issues in dengue vaccination. Curr Opin Infect Dis 2013; 26(5):429-34; PMID:23963259; http://dx.doi.org/10.1097/01.qco.0000433310.28771.cc
   PubMed Web of Science ®Google Scholar
• Bhoomiboonchoo P, Nisalak A, Chansatiporn N, Yoon IK, Kalayanarooj S, Thipayamongkolgul M, Endy T, Rothman AL, Green S, Srikiatkhachorn A, et al. Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994-2010. BMC Public Health 2015; 15:250
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, Jumnainsong A, Edwards C, Quyen NT, Duangchinda T, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 2015; 16(2):170-7; PMID:25501631; http://dx.doi.org/10.1038/ni.3058
   PubMed Web of Science ®Google Scholar
• Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, Kwissa M, Pulendran B, Wilson PC, Wittawatmongkol O, et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol 2012; 86(6):2911-8; PMID:22238318; http://dx.doi.org/10.1128/JVI.06075-11
   PubMed Web of Science ®Google Scholar
• Xu M, Hadinoto V, Appanna R, Joensson K, Toh YX, Balakrishnan T, Ong SH, Warter L, Leo YS, Wang CI, et al. Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes. J Immunol 2012; 189(12):5877-85: Epub 2012/11/16; PMID:23152560; http://dx.doi.org/10.4049/jimmunol.1201688
   PubMed Web of Science ®Google Scholar
• Toh YX, Gan V, Balakrishnan T, Zuest R, Poidinger M, Wilson S, Appanna R, Thein TL, Ong AK, Ng LC, et al. Dengue serotype cross-reactive, anti-e protein antibodies confound specific immune memory for 1 year after infection. Front Immunol 2014; 5:388; PMID:25177321; http://dx.doi.org/10.3389/fimmu.2014.00388
   PubMed Web of Science ®Google Scholar
• Biswas HH, Ortega O, Gordon A, Standish K, Balmaseda A, Kuan G, Harris E. Early clinical features of dengue virus infection in nicaraguan children: a longitudinal analysis. PLoS Negl Trop Dis 2012; 6(3):e1562; PMID:22413033; http://dx.doi.org/10.1371/journal.pntd.0001562
   PubMedGoogle Scholar
• Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, Kuan G, Gordon A, Balmaseda A, Harris E. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis 2013; 7(8):e2357. Epub 2013/08/21; http://dx.doi.org/10.1371/journal.pntd.0002357
   PubMed Web of Science ®Google Scholar
• Olkowski S, Forshey BM, Morrison AC, Rocha C, Vilcarromero S, Halsey ES, Kochel TJ, Scott TW, Stoddard ST. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 2013; 208(6):1026-33. Epub 2013/06/19; PMID:23776195; http://dx.doi.org/10.1093/infdis/jit273
   PubMed Web of Science ®Google Scholar
• Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH, Jarman RG, Srikiatkhachorn A, Mammen MP, Darunee B, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 2014; 209(3):360-8. Epub 2013/08/22; PMID:23964110; http://dx.doi.org/10.1093/infdis/jit436
   PubMed Web of Science ®Google Scholar
• Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, Low CY, Oh ML, Bouckenooghe A, Wartel TA, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Human Vaccines Immunotherapeutics 2012; 8(9):1259-71; PMID:22894958; http://dx.doi.org/10.4161/hv.21224
   PubMed Web of Science ®Google Scholar
• Halstead SB. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 2013; 31(41):4501-7. Epub 2013/07/31; PMID:23896423; http://dx.doi.org/10.1016/j.vaccine.2013.06.079
   PubMed Web of Science ®Google Scholar
• Kreil TR, Burger I, Bachmann M, Fraiss S, Eibl MM. Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin Exp Immunol 1997; 110(3):358-61; PMID:9409636; http://dx.doi.org/10.1046/j.1365-2249.1997.4311446.x
   PubMed Web of Science ®Google Scholar
• Saeland E, Jakobsen H, Ingolfsdottir G, Sigurdardottir ST, Jonsdottir I. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J Infect Dis 2001; 183(2):253-60; PMID:11110649; http://dx.doi.org/10.1086/317934
   PubMed Web of Science ®Google Scholar
• Zellweger RM, Shresta S. Mouse models to study dengue virus immunology and pathogenesis. Front Immunol 2014; 5:151; PMID:24782859; http://dx.doi.org/10.3389/fimmu.2014.00151
   PubMed Web of Science ®Google Scholar
• Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol 2015; 15(3):149-59; PMID:25677494; http://dx.doi.org/10.1038/nri3802
   PubMed Web of Science ®Google Scholar
• Balakrishnan T, Bela-Ong DB, Toh YX, Flamand M, Devi S, Koh MB, Hibberd ML, Ooi EE, Low JG, Leo YS, et al. Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection. PLoS One 2011; 6(12):e29430. Epub 2012/01/05; PMID:22216280; http://dx.doi.org/10.1371/journal.pone.0029430
   PubMedGoogle Scholar
• Jahnmatz M, Kesa G, Netterlid E, Buisman AM, Thorstensson R, Ahlborg N. Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses. J Immunol Methods 2013; 391(1-2):50-9; PMID:23454005; http://dx.doi.org/10.1016/j.jim.2013.02.009
   PubMed Web of Science ®Google Scholar
• Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006; 6(3):231-43; PMID:16498452; http://dx.doi.org/10.1038/nri1783
   PubMed Web of Science ®Google Scholar
• Garcia-Bates TM, Cordeiro MT, Nascimento EJ, Smith AP, Soares de Melo KM, McBurney SP, Evans JD, Marques ET, Jr, Barratt-Boyes SM. Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients. J Immunol 2013; 190(1):80-7. Epub 2012/12/04; PMID:23203929; http://dx.doi.org/10.4049/jimmunol.1103350
   PubMed Web of Science ®Google Scholar
• Kwissa M, Nakaya HI, Onlamoon N, Wrammert J, Villinger F, Perng GC, Yoksan S, Pattanapanyasat K, Chokephaibulkit K, Ahmed R, et al. Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe 2014; 16(1):115-27; PMID:24981333; http://dx.doi.org/10.1016/j.chom.2014.06.001
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A 2013; 110(22):E2046-53. Epub 2013/04/13
   PubMed Web of Science ®Google Scholar
• Dung NT, Duyen HT, Thuy NT, Ngoc TV, Chau NV, Hien TT, Rowland-Jones SL, Dong T, Farrar J, Wills B, et al. Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J Immunol 2010; 184(12):7281-7. Epub 2010/05/21; PMID:20483770; http://dx.doi.org/10.4049/jimmunol.0903262
   PubMed Web of Science ®Google Scholar
• Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW, Teo GH, Gan VC, Lye DC, Leo YS, et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol 2013; 87(5):2693-706. Epub 2012/12/21
   PubMed Web of Science ®Google Scholar
• Konishi E. Memory B cells: a proposed new immunological correlate for protective efficacy of Japanese encephalitis vaccine. Expert Rev Vaccines 2013; 12(8):871-3; PMID:23944374; http://dx.doi.org/10.1586/14760584.2013.814828
   PubMed Web of Science ®Google Scholar
• Mathew A, West K, Kalayanarooj S, Gibbons RV, Srikiatkhachorn A, Green S, Libraty D, Jaiswal S, Rothman AL. B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis 2011; 204(10):1514-22. Epub 2011/09/21; PMID:21930609; http://dx.doi.org/10.1093/infdis/jir607
   PubMed Web of Science ®Google Scholar
• Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003; 171(10):4969-73; PMID:14607890; http://dx.doi.org/10.4049/jimmunol.171.10.4969
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Eng J Med 2007; 357(19):1903-15; http://dx.doi.org/10.1056/NEJMoa066092
   PubMed Web of Science ®Google Scholar
• Ito M, Takasaki T, Yamada K, Nerome R, Tajima S, Kurane I. Development and evaluation of fluorogenic TaqMan reverse transcriptase PCR assays for detection of dengue virus types 1 to 4. J Clin Microbiol 2004; 42(12):5935-7; PMID:15583346; http://dx.doi.org/10.1128/JCM.42.12.5935-5937.2004
   PubMed Web of Science ®Google Scholar
• Zust R, Toh YX, Valdes I, Cerny D, Heinrich J, Hermida L, Marcos E, Guillén G, Kalinke U, Shi PY, et al. Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test Dengue vaccines. J Virol 2014; 88(13):7276-85; PMID:24741106; http://dx.doi.org/10.1128/JVI.03827-13
   PubMed Web of Science ®Google Scholar